Seon Hwan Oh

Title: The Innovative Contributions of Seon Hwan Oh

Introduction

Seon Hwan Oh is a prominent inventor located in Daejeon, South Korea. With an impressive portfolio consisting of three patents, he has made significant strides in the field of biopharmaceutical innovation. His dedication to research and development is evident through his contributions to novel antibody therapies aimed at tackling critical health issues.

Latest Patents

Among his latest innovations, Seon Hwan Oh has developed a dual-target antibody that targets VEGFR-2 and DLL4. This cutting-edge invention not only includes a novel form of the antibody but also a gene encoding it, a recombinant expression vector, and host cells transformed with the vector. Furthermore, he has devised a method for producing this dual-target antibody, along with a pharmaceutical composition that employs it.

Another significant patent involves a human antibody specifically targeting c-Met and its preparation method. This c-Met-specific antibody, isolated from a human Fv(ScFv) phage library, exhibits high affinity and specificity, making it a valuable tool in controlling c-Met activity in vivo. The patent also encompasses a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, and a cultured cell used for producing the antibody.

Career Highlights

Seon Hwan Oh is currently affiliated with Pharmabcine Inc., a company that specializes in the development of innovative therapies. His work focuses on enhancing therapeutic efficacy through the use of advanced antibody technologies. His patents reflect his commitment to advancing the field of biomedicine.

Collaborations

Throughout his career, Seon Hwan Oh has collaborated with several talented individuals, including his coworkers Jin San Yoo and Weon Sup Lee. Together, they contribute to a dynamic research environment that fosters creativity and scientific advancement in their respective fields.

Conclusion

Seon Hwan Oh's contributions to the field of biopharmaceuticals through his innovative patents highlight the importance of targeted therapies in modern medicine. His work at Pharmabcine Inc. and collaborations with esteemed colleagues reinforce his status as a leading inventor committed to improving healthcare outcomes.